Top 100 medical and healthcare startups in USA
Feb 26, 2026
|
Like
19
1
Funding: $272.5M
Senti Bio is developing a new generation of cell and gene therapies for cancer patients. The company has created the Gene Circuit Technology Platform to create gene circuits that can be integrated into new drugs with increased precision. These gene circuits allow to precisely destroy cancer cells, spare healthy cells, increase target tissue specificity and/or provide control even after drug administration. Clinical and preclinical studies have demonstrated the efficacy of the identified gene circuits, which target both NK cells and T cells, allowing the company to select the right cell type for each indication. The company's portfolio includes cell therapies targeting difficult-to-treat myelodysplastic syndromes and acute myeloid leukemia, as well as solid tumors.
Senti Bio is developing a new generation of cell and gene therapies for cancer patients. The company has created the Gene Circuit Technology Platform to create gene circuits that can be integrated into new drugs with increased precision. These gene circuits allow to precisely destroy cancer cells, spare healthy cells, increase target tissue specificity and/or provide control even after drug administration. Clinical and preclinical studies have demonstrated the efficacy of the identified gene circuits, which target both NK cells and T cells, allowing the company to select the right cell type for each indication. The company's portfolio includes cell therapies targeting difficult-to-treat myelodysplastic syndromes and acute myeloid leukemia, as well as solid tumors.
2
Funding: $160M
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.
3
Funding: $125M
Ambros was created to test and market neridronate, a drug designed to reduce pain in complex regional pain syndrome type 1, in North America. The startup acquired the rights to this drug from the Italian company Abiogen (the drug is approved in Italy). CRPS-1, formerly known as reflex sympathetic dystrophy, is a rare disorder characterized by intense and sometimes continuous pain in the affected limb following a bone injury.
Ambros was created to test and market neridronate, a drug designed to reduce pain in complex regional pain syndrome type 1, in North America. The startup acquired the rights to this drug from the Italian company Abiogen (the drug is approved in Italy). CRPS-1, formerly known as reflex sympathetic dystrophy, is a rare disorder characterized by intense and sometimes continuous pain in the affected limb following a bone injury.
4
Funding: $75M
Altesa is an innovative, clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations - namely viral respiratory infections, starting with rhinovirus, the most common respiratory virus on the planet.
Altesa is an innovative, clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations - namely viral respiratory infections, starting with rhinovirus, the most common respiratory virus on the planet.
5
Funding: $16.2M
Lin is an online pain management platform offering personalized, evidence-based programs from experts. It matches patients with chronic pain with personalized pain recovery consultant to create a customized treatment plan. The consultant guides them throughout the program and multidisciplinary clinical team provides oversight. Although the platform uses artificial intelligence to scale, all care is provided by humans. Treatments are not medication-based, but rather brain-focused techniques and physical therapy. The company partners with healthcare providers and insurance companies to offer patients evidence-based, low-risk chronic pain treatments.
Lin is an online pain management platform offering personalized, evidence-based programs from experts. It matches patients with chronic pain with personalized pain recovery consultant to create a customized treatment plan. The consultant guides them throughout the program and multidisciplinary clinical team provides oversight. Although the platform uses artificial intelligence to scale, all care is provided by humans. Treatments are not medication-based, but rather brain-focused techniques and physical therapy. The company partners with healthcare providers and insurance companies to offer patients evidence-based, low-risk chronic pain treatments.
6
Funding: $2M
SpendRule, a contract intelligence platform, makes contracts the first line of defense against overpayments.
SpendRule, a contract intelligence platform, makes contracts the first line of defense against overpayments.
7
Funding: $1.8B
Nuvalent develops targeted therapies targeting clinically proven kinases in oncology. Its drugs are small molecules that precisely interact with the target kinase in the original tumor and the mutated target kinase in the drug-resistant tumor. This allows the drugs to treat both the original tumor and tumors with emerging resistance mutations. Structure-based design technology addresses the issue of kinase selectivity to minimize side effects and ensure durable treatment responses. The company's pipeline includes clinical trials against non-small cell lung cancer and the treatment of brain metastases.
Nuvalent develops targeted therapies targeting clinically proven kinases in oncology. Its drugs are small molecules that precisely interact with the target kinase in the original tumor and the mutated target kinase in the drug-resistant tumor. This allows the drugs to treat both the original tumor and tumors with emerging resistance mutations. Structure-based design technology addresses the issue of kinase selectivity to minimize side effects and ensure durable treatment responses. The company's pipeline includes clinical trials against non-small cell lung cancer and the treatment of brain metastases.
8
Funding: $578.8M
HistoSonics has developed Edison - noninvasive ultrasound therapy platform, which utilizes histotripsy to destroy target liver tumors at the subcellular level. This is a form of focused ultrasound utilizes high-amplitude, very short pulses to create a "bubble cloud" designed to mechanically disrupt and liquefy target liver tumors. These bubble clouds form and collapse in microseconds, generating mechanical forces strong enough to destroy tissue at the cellular and subcellular levels in a noninvasive and nonthermal manner. The Edison device provides continuous imaging, personalized treatment and physician guidance. Acquired by K5 Global
HistoSonics has developed Edison - noninvasive ultrasound therapy platform, which utilizes histotripsy to destroy target liver tumors at the subcellular level. This is a form of focused ultrasound utilizes high-amplitude, very short pulses to create a "bubble cloud" designed to mechanically disrupt and liquefy target liver tumors. These bubble clouds form and collapse in microseconds, generating mechanical forces strong enough to destroy tissue at the cellular and subcellular levels in a noninvasive and nonthermal manner. The Edison device provides continuous imaging, personalized treatment and physician guidance. Acquired by K5 Global
9
Funding: $452M
Talkiatry is a virtual mental health care platform with over 800 full-time psychiatrists. These specialists provide care for a variety of conditions, including anxiety, depression, insomnia, mood disorders, postpartum depression, pediatric mental health, bipolar disorder, OCD, PTSD and substance use disorders. Their work is powered by AI platform that facilitates interaction with patients between visits and monitors the quality and level of care provided. The startup also implements innovative payment models with insurance companies.
Talkiatry is a virtual mental health care platform with over 800 full-time psychiatrists. These specialists provide care for a variety of conditions, including anxiety, depression, insomnia, mood disorders, postpartum depression, pediatric mental health, bipolar disorder, OCD, PTSD and substance use disorders. Their work is powered by AI platform that facilitates interaction with patients between visits and monitors the quality and level of care provided. The startup also implements innovative payment models with insurance companies.
10
Funding: $219.3M
Garner Health is a provider of healthcare services used to help employers give their employees a better healthcare experience.
Garner Health is a provider of healthcare services used to help employers give their employees a better healthcare experience.
11
Funding: $200M
AirNexis has exclusive rights to develop AN01- drug for chronic obstructive pulmonary disease (COPD) outside of China from Haisco Pharmaceutical Group. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through a dual mechanism of action (MOA) that promotes bronchodilation and reduces the release of inflammatory factors.
AirNexis has exclusive rights to develop AN01- drug for chronic obstructive pulmonary disease (COPD) outside of China from Haisco Pharmaceutical Group. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through a dual mechanism of action (MOA) that promotes bronchodilation and reduces the release of inflammatory factors.
12
Funding: $182.3M
Actuate Therapeutics develops molecular drugs for cancer treatment. Its lead drug, elraglusib (a GSK-3 inhibitor), targets multiple molecular pathways in cancer cells involved in promoting tumor growth and developing resistance to traditional anticancer drugs and chemotherapy. Elraglusib is also considered a mediator of antitumor immunity by inhibiting multiple immune checkpoints and regulating immune cell function. Actuate has demonstrated promising results in the treatment of pancreatic cancer, childhood malignancies, metastatic salivary gland carcinoma and melanoma.
Actuate Therapeutics develops molecular drugs for cancer treatment. Its lead drug, elraglusib (a GSK-3 inhibitor), targets multiple molecular pathways in cancer cells involved in promoting tumor growth and developing resistance to traditional anticancer drugs and chemotherapy. Elraglusib is also considered a mediator of antitumor immunity by inhibiting multiple immune checkpoints and regulating immune cell function. Actuate has demonstrated promising results in the treatment of pancreatic cancer, childhood malignancies, metastatic salivary gland carcinoma and melanoma.
13
Funding: $63.2M
Anterior is an AI-powered healthcare administration platform that helps approve health insurance for medical procedures.
Anterior is an AI-powered healthcare administration platform that helps approve health insurance for medical procedures.
14
Funding: $15.2M
BioVaxys develops immunotherapeutic cancer vaccines targeting lymphoma and ovarian cancer. The company develops them using its proprietary DPX delivery platform. Unlike conventional emulsions or lipid nanoparticles that release their contents systemically, DPX is fully synthetic and compatible with peptides, proteins, mRNA, virus-like particles and small molecules. It is ideal for mRNA delivery, remaining localized at the injection site with superior stability compared to LDL. Maveropepimute-S, the company's lead clinical drug based on this platform, demonstrated an overall response rate of 21% and a disease control rate of 63% in recurrent ovarian cancer. In relapsed/refractory DLBL, the combination of MVP-S and Keytruda achieved complete remission in 3 of 6 evaluable patients. This means that no detectable cancer cells remained after treatment.
BioVaxys develops immunotherapeutic cancer vaccines targeting lymphoma and ovarian cancer. The company develops them using its proprietary DPX delivery platform. Unlike conventional emulsions or lipid nanoparticles that release their contents systemically, DPX is fully synthetic and compatible with peptides, proteins, mRNA, virus-like particles and small molecules. It is ideal for mRNA delivery, remaining localized at the injection site with superior stability compared to LDL. Maveropepimute-S, the company's lead clinical drug based on this platform, demonstrated an overall response rate of 21% and a disease control rate of 63% in recurrent ovarian cancer. In relapsed/refractory DLBL, the combination of MVP-S and Keytruda achieved complete remission in 3 of 6 evaluable patients. This means that no detectable cancer cells remained after treatment.
15
Funding: $555.6M
CG Oncology develops oncolytic immunotherapies for patients with advanced bladder cancer. Its flagship drug Cretostimogen is an intravesically administered oncolytic immunotherapy with a dual mechanism of action. It selectively replicates and lyses bladder cancer cells. The rupture of cancer cells can then release tumor-derived antigens, along with GM-CSF, which can stimulate a systemic antitumor immune response involving the body's immune system. CG Oncology has a robust clinical trial program with a developed pipeline to study the safety and efficacy of Cretostimogen. It has received FSA Fast Track and Breakthrough Therapy designations from the FDA.
CG Oncology develops oncolytic immunotherapies for patients with advanced bladder cancer. Its flagship drug Cretostimogen is an intravesically administered oncolytic immunotherapy with a dual mechanism of action. It selectively replicates and lyses bladder cancer cells. The rupture of cancer cells can then release tumor-derived antigens, along with GM-CSF, which can stimulate a systemic antitumor immune response involving the body's immune system. CG Oncology has a robust clinical trial program with a developed pipeline to study the safety and efficacy of Cretostimogen. It has received FSA Fast Track and Breakthrough Therapy designations from the FDA.
16
Funding: $209M
Ikena Oncology is developing novel immunometabolic therapies. Its flagship drug IMG-007 is a monoclonal antibody against OX40 with an extended half-life (5 weeks) for patients with immunological, autoimmune and inflammatory diseases. IMG-007 contains a modified Fc region that blocks ADCC function, meaning signaling by activated T cells is weakened without destroying or depleting T cells. This solution has the potential to improve tolerability and increase the range of measurement, leading to the use of higher doses, increased efficacy and improved safety. The company's primary target is atopic dermatitis. In a proof-of-concept clinical trial in patients with moderate to severe atopic dermatitis, three doses of IMG-007 administered over a one-month period resulted in symptom reduction in the majority of patients. Ikena Oncology was acquired by ImageneBio
Ikena Oncology is developing novel immunometabolic therapies. Its flagship drug IMG-007 is a monoclonal antibody against OX40 with an extended half-life (5 weeks) for patients with immunological, autoimmune and inflammatory diseases. IMG-007 contains a modified Fc region that blocks ADCC function, meaning signaling by activated T cells is weakened without destroying or depleting T cells. This solution has the potential to improve tolerability and increase the range of measurement, leading to the use of higher doses, increased efficacy and improved safety. The company's primary target is atopic dermatitis. In a proof-of-concept clinical trial in patients with moderate to severe atopic dermatitis, three doses of IMG-007 administered over a one-month period resulted in symptom reduction in the majority of patients. Ikena Oncology was acquired by ImageneBio
17
Funding: $113M
VieCure develops Halo Intelligence - AI-powered software for oncology care. It provides physicians with a clinical analytics system and an electronic medical record for oncology patients, enabling them to develop personalized treatment plans. The platform integrates real-time clinical decision support, practice operating system, codified curated knowledge base, physician mobile app, teleoncology, patient mobile app and AI-powered analytics system.
VieCure develops Halo Intelligence - AI-powered software for oncology care. It provides physicians with a clinical analytics system and an electronic medical record for oncology patients, enabling them to develop personalized treatment plans. The platform integrates real-time clinical decision support, practice operating system, codified curated knowledge base, physician mobile app, teleoncology, patient mobile app and AI-powered analytics system.
18
Funding: $100M
Azalea Therapeutics is a biotech company co-founded by Nobel laureate and CRISPR co-creator Jennifer Doudna to develop a revolutionary cancer vaccine - a single injection that reprograms a patient's T cells directly within the body (in vivo). The technology combines virus-like particles (EDVs) for precise delivery of the CRISPR editor and adeno-associated viruses, which allow genes to be inserted into precisely defined sections of DNA. The combination of these technologies enables a single injection that modifies T cells while preserving their natural behavior. The company is also exploring the possibility of applying the technology to hematopoietic stem cells and B cells. Azalea stands out from its competitors thanks to its unique ability to precisely program gene placement in immune cells.
Azalea Therapeutics is a biotech company co-founded by Nobel laureate and CRISPR co-creator Jennifer Doudna to develop a revolutionary cancer vaccine - a single injection that reprograms a patient's T cells directly within the body (in vivo). The technology combines virus-like particles (EDVs) for precise delivery of the CRISPR editor and adeno-associated viruses, which allow genes to be inserted into precisely defined sections of DNA. The combination of these technologies enables a single injection that modifies T cells while preserving their natural behavior. The company is also exploring the possibility of applying the technology to hematopoietic stem cells and B cells. Azalea stands out from its competitors thanks to its unique ability to precisely program gene placement in immune cells.
19
Funding: $75M
Neok is a spin-off of Korean biotech ABL, that paired its antibody skills with linker-payload technology to build a pipeline of ADCs. Neok was started with two ADC-candidates from ABL and plans to test them and deliver the first human data in 2027. The drugs target thoracic, gastrointestinal and gynecological cancers via ROR1, EGFR and MUC1 proteins. The expression of these proteins by some healthy cells makes on-target, off-tumor toxicity a concern for drugs that engage the receptor. But, in theory, Neok's bispecific design (which is fine-tuned for each target antigen pair) could improve safety. This dual-targeting strategy has the potential to target a wider range of tumors, overcome drug resistance.
Neok is a spin-off of Korean biotech ABL, that paired its antibody skills with linker-payload technology to build a pipeline of ADCs. Neok was started with two ADC-candidates from ABL and plans to test them and deliver the first human data in 2027. The drugs target thoracic, gastrointestinal and gynecological cancers via ROR1, EGFR and MUC1 proteins. The expression of these proteins by some healthy cells makes on-target, off-tumor toxicity a concern for drugs that engage the receptor. But, in theory, Neok's bispecific design (which is fine-tuned for each target antigen pair) could improve safety. This dual-targeting strategy has the potential to target a wider range of tumors, overcome drug resistance.
20
Funding: $72M
Link Cell Therapies develops CAR-T cell therapies for patients with solid tumors. The company has developed unique AND gate technology that requires co-expression of cancer targets to ensure cellular cytotoxicity and greater tumor specificity. It enables safe targeting of multiple antigens that are co-expressed on cancer cells but have no or minimal overlap in normal healthy tissue. Combined with additional platforms in development, the company is advancing number of promising therapeutic programs that promise to unlock the potential of CAR T therapy in a variety of important oncological diseases, including solid tumors and certain hematological malignancies. Johnson & Johnson is a major investor in the startup.
Link Cell Therapies develops CAR-T cell therapies for patients with solid tumors. The company has developed unique AND gate technology that requires co-expression of cancer targets to ensure cellular cytotoxicity and greater tumor specificity. It enables safe targeting of multiple antigens that are co-expressed on cancer cells but have no or minimal overlap in normal healthy tissue. Combined with additional platforms in development, the company is advancing number of promising therapeutic programs that promise to unlock the potential of CAR T therapy in a variety of important oncological diseases, including solid tumors and certain hematological malignancies. Johnson & Johnson is a major investor in the startup.
21
Funding: $51.9M
DermaSensor is developing a handheld device for practitioners for detection of skin cancer risk. It is the first FDA-cleared AI-powered skin cancer diagnostic device that enables objective referral prioritization using a 0-10 cancer risk assessment scale. A total of five spectral data points are captured from each skin lesion. The DermaSensor algorithm analyzes the spectral data and provides a skin cancer risk assessment in seconds. The tip of the device reflects and records short bursts of light from the lesion's cellular and subcellular contents. The light is analyzed by a built-in computer, providing information that helps physicians evaluate skin lesions (including melanomas, squamous cell carcinomas and basal cell carcinomas) to determine referral.
DermaSensor is developing a handheld device for practitioners for detection of skin cancer risk. It is the first FDA-cleared AI-powered skin cancer diagnostic device that enables objective referral prioritization using a 0-10 cancer risk assessment scale. A total of five spectral data points are captured from each skin lesion. The DermaSensor algorithm analyzes the spectral data and provides a skin cancer risk assessment in seconds. The tip of the device reflects and records short bursts of light from the lesion's cellular and subcellular contents. The light is analyzed by a built-in computer, providing information that helps physicians evaluate skin lesions (including melanomas, squamous cell carcinomas and basal cell carcinomas) to determine referral.
22
Funding: $31.3M
WearLinq produces wearable devices for health monitoring and diagnostics, in particular wireless 6-lead clinical ECG monitor and monitor eWave. It pairs with user's phone, transmitting real-time data and reports for up to 48 hours to doctors. The company claims the wireless monitor can last more than five days on a single charge. The device can help detect arrhythmias, but the company plans to expand its use in the future. WearLinq already received FDA clearance for the device to continuously monitor cardiac activity in individuals who may be asymptomatic or experience transient symptoms such as syncope, palpitations, dizziness, shortness of breath, lightheadedness, weakness, fatigue or anxiety.
WearLinq produces wearable devices for health monitoring and diagnostics, in particular wireless 6-lead clinical ECG monitor and monitor eWave. It pairs with user's phone, transmitting real-time data and reports for up to 48 hours to doctors. The company claims the wireless monitor can last more than five days on a single charge. The device can help detect arrhythmias, but the company plans to expand its use in the future. WearLinq already received FDA clearance for the device to continuously monitor cardiac activity in individuals who may be asymptomatic or experience transient symptoms such as syncope, palpitations, dizziness, shortness of breath, lightheadedness, weakness, fatigue or anxiety.
23
Funding: $335.4M
Kite Pharma develops and produces immune-based cell therapies to treat cancer. Each cell therapy developed by the company is individually tailored to each patient and one-time injected. The CAR T-cell therapy manufacturing process involves collecting the patient's white blood cells, isolating and activating the T-cells, modifying the T-cells with a chimeric antigen receptor gene, culturing and expanding the T-cells and administering the modified T-cells to the same patient. Kite has a state-of-the-art manufacturing facility with full production cycle and global logistics network. The company's portfolio includes two drugs for the treatment of blood diseases, specifically diffuse large B-cell lymphoma, mantle cell lymphoma and acute lymphoblastic leukemia. The company's pipeline includes clinical trials for the treatment of lymphoma, myeloma and leukemia. Acquired by Gilead Sciences
Kite Pharma develops and produces immune-based cell therapies to treat cancer. Each cell therapy developed by the company is individually tailored to each patient and one-time injected. The CAR T-cell therapy manufacturing process involves collecting the patient's white blood cells, isolating and activating the T-cells, modifying the T-cells with a chimeric antigen receptor gene, culturing and expanding the T-cells and administering the modified T-cells to the same patient. Kite has a state-of-the-art manufacturing facility with full production cycle and global logistics network. The company's portfolio includes two drugs for the treatment of blood diseases, specifically diffuse large B-cell lymphoma, mantle cell lymphoma and acute lymphoblastic leukemia. The company's pipeline includes clinical trials for the treatment of lymphoma, myeloma and leukemia. Acquired by Gilead Sciences
24
Funding: $281M
Paradigm creates an intelligent platform that enables all patients to participate in clinical trials and helps biotech companies improve their efficiency. The platform uses AI to automate patient recruitment and evaluate the feasibility of conducting trials at sites. The system enables providers to visualize their entire research portfolio, identify opportunities for patients not yet enrolled in trials, analyze the effectiveness of their clinical trial portfolio compared to expected enrollment rates and automate the completion of electronic data collection forms. Paradigm specializes in oncology research, cardiovascular diseases, metabolic disorders and neuroscience.
Paradigm creates an intelligent platform that enables all patients to participate in clinical trials and helps biotech companies improve their efficiency. The platform uses AI to automate patient recruitment and evaluate the feasibility of conducting trials at sites. The system enables providers to visualize their entire research portfolio, identify opportunities for patients not yet enrolled in trials, analyze the effectiveness of their clinical trial portfolio compared to expected enrollment rates and automate the completion of electronic data collection forms. Paradigm specializes in oncology research, cardiovascular diseases, metabolic disorders and neuroscience.
25
Funding: $106M
Totus Medicines develops precision oral therapeutics for cancer treatment. The company uses own drug discovery platform OmniDEL, which utilizes artificial intelligence/machine learning and innovative DNA-encoded covalent library technology to search for small molecule drugs. The startup conducts ultra-high-throughput cell-based screening of these molecules using its proprietary labeling technology for cellular analysis. The company's flagship drug, TOS-358, is a precision oral drug for the treatment of cancers with PI3Kα mutations (the most frequently mutated oncogene in a wide range of cancers, for which there are currently no drugs that provide potent, specific and long-lasting inhibition without significant toxicity). TOS-358 is currently in clinical trials for the treatment of hormone receptor-positive breast, endometrial and head and neck cancers expressing PI3K-alpha mutations.
Totus Medicines develops precision oral therapeutics for cancer treatment. The company uses own drug discovery platform OmniDEL, which utilizes artificial intelligence/machine learning and innovative DNA-encoded covalent library technology to search for small molecule drugs. The startup conducts ultra-high-throughput cell-based screening of these molecules using its proprietary labeling technology for cellular analysis. The company's flagship drug, TOS-358, is a precision oral drug for the treatment of cancers with PI3Kα mutations (the most frequently mutated oncogene in a wide range of cancers, for which there are currently no drugs that provide potent, specific and long-lasting inhibition without significant toxicity). TOS-358 is currently in clinical trials for the treatment of hormone receptor-positive breast, endometrial and head and neck cancers expressing PI3K-alpha mutations.
26
Funding: $305M
Parabilis Medicines has developed drug discovery platform for alpha-helical-linked peptides, primarily composed of specially selected non-canonical amino acids. Using this platform, Parabilis has assembled a large set of non-canonical amino acids and has hundreds of proprietary linkers for stabilizing peptides in the alpha-helical conformation. To fully exploit this diversity, the company has developed a suite of specialized experimental systems that can generate massive amounts of data on a wide range of drug properties, providing both input for building artificial intelligence models and serving as a high-throughput platform for empirically validating model predictions. As a pilot project, the company is advancing a drug against desmoid tumors.
Parabilis Medicines has developed drug discovery platform for alpha-helical-linked peptides, primarily composed of specially selected non-canonical amino acids. Using this platform, Parabilis has assembled a large set of non-canonical amino acids and has hundreds of proprietary linkers for stabilizing peptides in the alpha-helical conformation. To fully exploit this diversity, the company has developed a suite of specialized experimental systems that can generate massive amounts of data on a wide range of drug properties, providing both input for building artificial intelligence models and serving as a high-throughput platform for empirically validating model predictions. As a pilot project, the company is advancing a drug against desmoid tumors.
27
Funding: $280.8M
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
28
Funding: $253M
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
29
Funding: $231M
Chai Discovery develops AI models that predict and reprogram biochemical molecule interactions. Chai’s goal is to shorten the drug development timeline so that potential new medicines enter first-in-human studies and reach the market quicker. It can design molecules that have needed properties and tackle challenging targets that have been out of reach. The team has already used its flagship model Chai 2 to develop monoclonal antibodies aimed against tough-to-drug targets, and (accoring to the company) the new designs have properties similar to known antibody drugs.
Chai Discovery develops AI models that predict and reprogram biochemical molecule interactions. Chai’s goal is to shorten the drug development timeline so that potential new medicines enter first-in-human studies and reach the market quicker. It can design molecules that have needed properties and tackle challenging targets that have been out of reach. The team has already used its flagship model Chai 2 to develop monoclonal antibodies aimed against tough-to-drug targets, and (accoring to the company) the new designs have properties similar to known antibody drugs.
30
Funding: $96M
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
31
Funding: $11.5M
AiM Medical Robotics is developing portable, MRI-compatible surgical robot that can be useed in the MRI room and operating room. The company's goal is to improve outcomes for patients undergoing neurosurgery for functional brain disorders (Parkinson's disease, epilepsy, etc.) and brain cancer. It also can save hospitals money by eliminating errors and reducing procedure time. AiM's robotic platform can integrate into existing workflow and provide surgeons with real-time intraoperative MRI visualization combined with robotic control to ensure precise placement of neurostimulation electrodes, biopsies, tumor ablation and targeted intracranial delivery of therapeutic drugs. The system leverages AI to provide surgeons with predictive information in real time.
AiM Medical Robotics is developing portable, MRI-compatible surgical robot that can be useed in the MRI room and operating room. The company's goal is to improve outcomes for patients undergoing neurosurgery for functional brain disorders (Parkinson's disease, epilepsy, etc.) and brain cancer. It also can save hospitals money by eliminating errors and reducing procedure time. AiM's robotic platform can integrate into existing workflow and provide surgeons with real-time intraoperative MRI visualization combined with robotic control to ensure precise placement of neurostimulation electrodes, biopsies, tumor ablation and targeted intracranial delivery of therapeutic drugs. The system leverages AI to provide surgeons with predictive information in real time.
32
Funding: $3.9B
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
33
Funding: $3.5B
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
34
Funding: $3.4B
Genetix Biotherapeutics (formerly Bluebird Bio) develops gene therapies for rare genetic diseases using patient's own blood stem cells. The cells are harvested, modified outside the body to add working copies of the affected gene and then reintroduced into the patient, restoring the function of the affected gene. The company specializes in the treatment of sickle cell anemia, beta thalassemia and cerebral adrenoleukodystrophy (CALD). Its unique, single-dose treatments are FDA approved and address the underlying cause of the disease and can provide significant, long-term benefits to patients. Acquired by The Carlyle Group
Genetix Biotherapeutics (formerly Bluebird Bio) develops gene therapies for rare genetic diseases using patient's own blood stem cells. The cells are harvested, modified outside the body to add working copies of the affected gene and then reintroduced into the patient, restoring the function of the affected gene. The company specializes in the treatment of sickle cell anemia, beta thalassemia and cerebral adrenoleukodystrophy (CALD). Its unique, single-dose treatments are FDA approved and address the underlying cause of the disease and can provide significant, long-term benefits to patients. Acquired by The Carlyle Group
35
Funding: $3B
Altos Labs is working on biological reprogramming technology to essentially prolong human life
Altos Labs is working on biological reprogramming technology to essentially prolong human life
36
Funding: $2.8B
Exact Sciences creates noninvasive screening tests for the early detection of cancer. The company's flagship product, Cologuard test, uses a biomarker panel that analyzes a stool sample for 10 DNA markers, as well as fecal blood (hemoglobin). It detects colon cancer even in its early stages, when it is more treatable. The test can be administered at home without special training. Cologuard includes a built-in patient management program with support. The test is based on proprietary QuARTS (quantitative allele-specific amplification of target and real-time signal) technology, which efficiently amplifies and quantifies two distinct methylated DNA markers (NDRG4 and BMP3), as well as seven different point mutations of the KRAS gene. The beta-actin gene (ACTB) serves as a reference marker for quantifying the total amount of human DNA in each sample.
Exact Sciences creates noninvasive screening tests for the early detection of cancer. The company's flagship product, Cologuard test, uses a biomarker panel that analyzes a stool sample for 10 DNA markers, as well as fecal blood (hemoglobin). It detects colon cancer even in its early stages, when it is more treatable. The test can be administered at home without special training. Cologuard includes a built-in patient management program with support. The test is based on proprietary QuARTS (quantitative allele-specific amplification of target and real-time signal) technology, which efficiently amplifies and quantifies two distinct methylated DNA markers (NDRG4 and BMP3), as well as seven different point mutations of the KRAS gene. The beta-actin gene (ACTB) serves as a reference marker for quantifying the total amount of human DNA in each sample.
37
Funding: $2.4B
Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.
Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.
38
Funding: $2.4B
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
39
Funding: $2.3B
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
40
Funding: $2.3B
Devoted Health is a healthcare company serving seniors and giving them a health care plan with personal guides and world-class technology.
Devoted Health is a healthcare company serving seniors and giving them a health care plan with personal guides and world-class technology.
41
Funding: $2.3B
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.
42
Funding: $2B
Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
43
Funding: $2B
The mission of Grail is to enable the early detection of cancer in asymptomatic individuals through a blood screen – with the goal of massively decreasing global cancer mortality by detection at a curable stage. Grail will leverage the power of Illumina next-generation sequencing technology, the best talent in the field and the passion of its leadership to deliver on that promise.
The mission of Grail is to enable the early detection of cancer in asymptomatic individuals through a blood screen – with the goal of massively decreasing global cancer mortality by detection at a curable stage. Grail will leverage the power of Illumina next-generation sequencing technology, the best talent in the field and the passion of its leadership to deliver on that promise.
44
Funding: $2B
Oscar is a health insurance company that employs technology, design, and data to humanize health care.
Oscar is a health insurance company that employs technology, design, and data to humanize health care.
45
Funding: $1.9B
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
46
Funding: $1.9B
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease.
47
Funding: $1.9B
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology.
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology.
48
Funding: $1.6B
Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers.
Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers.
49
Funding: $1.6B
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
